Menu Search
Equities

Baxter International Inc

BTL:FRA

Baxter International Inc

Actions
  • Price (EUR)61.74
  • Today's Change-1.46 / -2.31%
  • Shares traded337.00
  • 1 Year change-9.29%
  • Beta--
Data delayed at least 15 minutes, as of Jun 29 2022 08:16 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Baxter International Inc. through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s segments include Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia-Pacific), and Hillrom. The Americas, EMEA and APAC segments provide a portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.

  • Revenue in USD (TTM)13.55bn
  • Net income in USD1.06bn
  • Incorporated1931
  • Employees60.00k
  • Location
    Baxter International IncDF2-1W, ONE BAXTER PKWYDEERFIELD 60015United StatesUSA
  • Phone+1 (847) 948-2000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.baxter.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BAX:NYQ since
announced		Transaction
value
Hill-Rom Holdings IncDeal completed02 Sep 202102 Sep 2021Deal completed-15.19%10.42bn
Data delayed at least 15 minutes, as of Jun 29 2022 21:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.